Stage IV/Metastatic Breast Cancer, Open to All To Contribute
Archives for January 2020
Discussion List
-
FDA Approves Enhertu for Unresectable or Pretreated HER2+ MBC
FDA Approves Enhertu for Unresectable or Pretreated Metastatic HER2-Positive Breast Cancer January 2, 2020 On Dec. 20, 2019, the U.S. Food and Drug Administration approved Enhertu (chemical name: fam-trastuzumab deruxtecan-nxki) to treat people diagnosed with unresectable HER2-positive breast cancer or metastatic…
Join Us on Zoom: Upcoming virtual meetups. Read more...